Trials
Search / Trial NCT05650164

Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART2)

Launched by MERCK HEALTHCARE KGAA, DARMSTADT, GERMANY, AN AFFILIATE OF MERCK KGAA, DARMSTADT, GERMANY · Dec 6, 2022

Apply for Trial

Trial Information

Current as of February 05, 2025

Completed

Keywords

Retrospective Multicenter Non Interventional Medical Chart Review Japan Metastatic Renal Cell Cancer(m Rcc) Avelumab Axitinib First Line Therapy Standard Care In Real World Clinical Setting

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • • 1. Diagnoses of mRCC based on the General Rule for Clinical and Pathological Studies on RCC (Fifth Edition) before receiving avelumab plus axitinib as first-line therapy. Patients with mRCC who have unresectable disease, either unresectable locally advanced or metastatic disease.
  • • 2. Age over 18 years at the time of the first administration of avelumab plus axitinib as firstline therapy for mRCC (baseline).
  • • 3. Index date from 20 December 2019 to 17 October 2022.
  • Exclusion Criteria:
  • • 1. Patients participating in a prospective interventional clinical trial assessing an investigational product during the observation period.
  • • 2. Patients (or a patient's legally representative) refusing to provide patient data during the consent process.

Trial Officials

Medical Responsible

Study Director

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

About Merck Healthcare Kgaa, Darmstadt, Germany, An Affiliate Of Merck Kgaa, Darmstadt, Germany

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, is a leading global healthcare company dedicated to advancing medical research and innovation. With a strong commitment to improving patient outcomes, the organization focuses on developing cutting-edge therapies and solutions across various therapeutic areas, including oncology, neurology, and immunology. Leveraging its extensive expertise in pharmaceuticals and life sciences, Merck Healthcare aims to address unmet medical needs through rigorous clinical trials and collaborations, driving progress in healthcare and enhancing the quality of life for patients worldwide.

Locations

Hiroshima, , Japan

Fukuoka, , Japan

Shinjuku Ku, Tokyo, Japan

Sapporo, Hokkaido, Japan

Kobe, Hyogo, Japan

Nagoya, Aichi, Japan

Suita City, Osaka, Japan

Osakasayama, Osaka, Japan

Kurume Shi, Fukuoka, Japan

Asahikawa, Hokkaido, Japan

Kobe City, Hyogo, Japan

Kanazawa Shi, Ishikawa, Japan

Yamagata Shi, Yamagata, Japan

Hirosaki, Aomori, Japan

Kyoto, , Japan

Wakayama Shi, Wakayama, Japan

Saitama City, Saitama, Japan

Kyoto Shi, Kyoto, Japan

Nankoku, Kōchi, Japan

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials